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Background:Whether infection with SARS-CoV-2 leads to excess risk of requiring hospitalization or intensive
care in persons with diabetes has not been reported, nor have risk factors in diabetes associated with
increased risk for these outcomes.
Methods:We included 44,639 and 411,976 adult patients with type 1 and type 2 diabetes alive on Jan 1, 2020,
and compared them to controls matched for age, sex, and county of residence (n=204,919 and 1,948,900).
Age- and sex-standardized rates for COVID-19 related hospitalizations, admissions to intensive care and
death, were estimated and hazard ratios were calculated using Cox regression analyses.
Findings: There were 10,486 hospitalizations and 1,416 admissions into intensive care. A total of 1,175
patients with diabetes and 1,820 matched controls died from COVID-19, of these 532% had been hospitalized
and 107% had been in intensive care. Patients with type 2 diabetes, compared to controls, displayed an age-
and sex-adjusted hazard ratio (HR) of 222, 95%CI 213-232) of being hospitalized for COVID-19, which
decreased to HR 140, 95%CI 134-147) after further adjustment for sociodemographic factors, pharmacologi-
cal treatment and comorbidities, had higher risk for admission to ICU due to COVID-19 (age- and sex-
adjusted HR 249, 95%CI 222-279, decreasing to 142, 95%CI 125-162 after adjustment, and increased risk
for death due to COVID-19 (age- and sex-adjusted HR 219, 95%CI 203-236, complete adjustment 150,
95%CI 139-163). Age- and sex-adjusted HR for COVID-19 hospitalization for type 1 diabetes was 210, 95%CI
172-257), decreasing to 125, 95%CI 03097-162) after adjustment Patients with diabetes type 1 were twice
as likely to require intensive care for COVID-19, however, not after adjustment (HR 149, 95%CI 075-292),
and more likely to die (HR 290, 95% CI 16554-547) from COVID-19, but not independently of other factors
(HR 138, 95% CI 064-299). Among patients with diabetes, elevated glycated hemoglobin levels were associ-
ated with higher risk for most outcomes.
Interpretation: In this nationwide study, type 2 diabetes was independently associated with increased risk of
hospitalization, admission to intensive care and death for COVID-19. There were few admissions into inten-
sive care and deaths in type 1 diabetes, and although hazards were significantly raised for all three outcomes,
there was no independent risk persisting after adjustment for confounding factors.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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From the start of the COVID-19 pandemic in the first months of
2020 it has been apparent that the infection may represent a real
danger not only for the elderly but also for middle-aged adults [1-4],
where hospitalization rates and admissions to intensive care have
Research in context
Evidence before this study
The majority of all persons, with and without diabetes, infected
with SARS-CoV-2, survive and do not require hospitalization or
intensive care. Findings from multiple studies have shown that
people with both type 1 and type 2 diabetes have an increased
risk of in-hospital death, of death or a composite of mortality
and need of intensive care from COVID-19. Among persons
with diabetes of either type COVID-19-related mortality is asso-
ciated with older age, male sex, socioeconomic deprivation,
non-white ethnicity, established cardiovascular disease, and
impaired renal function, glycemic control and with both obesity
and underweight. However, from a public health point of view
COVID-19 presents a much more complex problem in that hos-
pitals are frequently overwhelmed, both with respect to total
beds but also to intensive care with an excessive toll on human
and other resources. To which extent deaths, hospitalizations,
and intensive care overlap will obviously depend on organiza-
tion of health care and care of the elderly, as well as reporting
on deaths, but with these limitations in mind, no studies have
attempted to report findings for people with and without dia-
betes separately for these outcomes. We searched the PubMed
and medRxiv using the search terms “COVID-19”, “SARS-CoV-
2”, “diabetes” (in the publication title) and (hospitalization OR
intensive care OR critical care OR mortality) for English-lan-
guage publications. We were unable to identify any study that
established risk of hospitalization, being in need of intensive
care, or death, separately for each outcome, compared to popu-
lation controls without diabetes.
Added value of this study
This is, to our knowledge, the first study to address to which
extent persons with diabetes type 1 and 2 have an excess risk
of being hospitalized, requiring intensive care, or die (in- or
outside hospital) compared to persons without diabetes from
the general population. We used data from a nationwide Swed-
ish diabetes registry with 90% coverage, analyzing a total of
44,478 patients with type 1 diabetes and 385,021 persons with
type 2 diabetes; comparing them with over 1.8 million controls
without diabetes, matched for age, sex, and county. Altogether,
3,587 people with diabetes and 6,899 controls were hospital-
ized, 469 with diabetes and 947 controls were admitted to
intensive care, with 1,175 with diabetes and 1,820 controls suc-
cumbing to COVID-19. Of all deaths, only 53% had been hospi-
talized and 11% had been in intensive care. Compared to
controls, individuals with type 2 diabetes were twice as likely
to be hospitalized, to require intensive care, and to die. After
adjustment for comorbidities and pharmacological treatment,
the excess risks were reduced but remained significant. Persons
with type 1 diabetes had excess risk of being hospitalized,
needing intensive care and a 3-fold risk to die compared to con-
trols, but after adjustment for covariates there was no signifi-
cant excess risk for either outcome; there were however only
21 cases requiring intensive care, and 21 deaths among those
with diabetes type 1; the latter at an average age of 71 years.
Among people with diabetes, poor metabolic control and obe-
sity were associated with worse outcomes.
Implications of all the available evidence
Patients with diabetes type 2, compared to population controls,
were 2 times more likely to require hospitalization, to be
admitted to intensive care and to die. This was partly, but not
entirely, due to comorbid conditions, differences in medica-
tions, and socioeconomic factors. Patients with type 1 diabetes
had 3 times higher death rates than expected; but this was con-
centrated among those older than 55 years. Good metabolic
control and maintaining a healthy weight are measures that
may prevent persons with diabetes from falling seriously ill or
die from COVID-19.
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tively mild in most infected people, initial reports from China, Italy
and USA indicated that some factors were strongly associated with
serious outcomes in those infected with the virus, not only older age,
but also cardiovascular disease, diabetes, hypertension and obesity
[5-9]. A common denominator for several of these disorders are
related to obesity, mainly diabetes, where increasing evidence shows
that hyperglycaemia is associated with higher risk of complications
and mortality from COVID-19 [5, 10, 11]. Even so, immunological and
pathophysiological effects of hyperglycaemia on COVID-19 infections
remain elusive, and studies are not unanimous that elevated blood
glucose contributes to worse prognosis [12, 13]. Understanding the
interplay between underlying cardiovascular conditions, clinical
characteristics, sociodemographic factors, pharmacological treatment
and cardiometabolic risk factors is essential for risk mitigation strate-
gies and generation of population-specific models for predicting risk
of severe COVID-19 cases.
Despite the lack of a formal lockdown, something which is cur-
rently not permitted by the Swedish constitution, and relying on vol-
untary recommendations only, the course of the pandemic in
Sweden in the spring and summer of 2020 was similar to many other
European countries that did apply strict lockdowns, with death rates
comparable to or lower than for example France, the UK, Italy, Spain,
and Belgium. Similar to other countries most deaths occurred among
the very old, many of them living in long-term care facilities.
Most population-based studies of the impact of COVID-19 have
reported data on in-hospital mortality [5, 6] or on a combination of
mortality and intensive care admission [14] but from a population
health perspective there are several other pressing concerns, not
least that hospitals are frequently overwhelmed, both with respect to
total beds and to need of intensive care, with an excessive toll on
human and other resources. To which extent deaths, hospitalizations,
and intensive care overlap will obviously depend on organization of
health care and care of the elderly, as well as reporting on deaths, but
so far, no studies have reported findings for people with and without
diabetes separately for these outcomes.
The National Diabetes Registry (NDR) in Sweden keeps track of over
90% of all individuals with diabetes in Sweden. The purpose of this
nationwide observational study was to compare standardized incidence
rates and excess risk of hospitalization, admission to intensive care and
mortality as a result of COVID-19 in patients with type 1 diabetes and
type 2 diabetes, compared to region-, age- and sex matched controls
from the general population, during the period January 1 to August 17,
2020. In addition, we set out to assess the partial effect of cardiovascular
risk factor for risk of hospitalization, admission to intensive care or
death from COVID-19, in patients with diabetes.
2. Methods
Data are available from the sources stated in the paper on request
to the data providers, fulfilling legal and regulatory requirements and
with permission from the Swedish Ethical Review Authority.
2.1. Data sources and study cohort
The NDR [15, 16] is a nationwide tool for quality control of diabe-
tes care in Sweden, with physicians and nurses annually reporting
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Detailed information on clinical characteristics, risk factors, and treat-
ments for patients with diabetes were retrieved from The National
Diabetes Register. Patients aged >18 years with at least one registra-
tion in the NDR between January 1, 1998 and January 1, 2020, and
who were alive at start of follow-up, i.e., January 1, 2020, were
included in the study. A flow chart regarding analyses and study
cohort is presented in Supplementary Figure S1.
Type 1 diabetes was defined according to epidemiologic criteria:
treatment with insulin and diagnosis at 30 years of age or younger.
Type 2 diabetes was also defined according to epidemiologic criteria:
treatment with diet, with or without the use of oral antihyperglyce-
mic agents, or treatment with insulin, with or without the use of oral
antihyperglycemic agents; the latter category applied only to patients
who were 40 years of age or older at the time of diabetes diagnosis.
Information with respect to comorbidities, medications, admis-
sion to intensive care unit, hospitalizations, and deaths was retrieved
from the Swedish Inpatient Register, the Swedish Intensive Care Reg-
istry (https://www.icuregswe.org/en/) with complete coverage of all
patients with COVID-19 intensive care in Sweden, the Swedish Cause
of Death Register and the Swedish Prescribed Drug Register. Socio-
economic factors were retrieved from the Longitudinal integrated
database for health insurance and labour market studies (LISA) regis-
try. Data linkage is virtually complete owing to the use of unique per-
sonal identification numbers, which are assigned to all Swedes at
birth or immigration.
At inclusion in the registry, each patient with diabetes was
matched for age, gender and county with five controls without diabe-
tes, randomly selected from the Swedish Total Population Registry
kept by Statistics Sweden. Separate controls were selected for the
cohort with type 1 diabetes and the cohort with type 2 diabetes; no
person served as a control in both analyses.
2.2. Outcomes
We assessed three primary outcomes: hospitalization, intensive
care unit admission and mortality due to COVID-19. Hospitalizations
for COVID-19 as a principal or contributory diagnosis and comorbid-
ities were retrieved from hospital discharge records with the use of
codes in the International Classification of Diseases, 9th Revision and
10th Revision. The Swedish Inpatient Registry includes all inpatient
admissions since 1987. The majority of cases that were admitted to
intensive care unit (958%) overlapped with hospitalization for
COVID-19. The specific hospital codes and anatomical therapeutic
chemical classification (ATC) codes are listed in Table S1 in the sup-
plementary appendix. Patients were followed until an event occurred
or until August 17, 2020, for all outcomes except intensive-care unit
admission due to COVID-19, for which registrations were available
until July 12, 2020.
2.3. Variables assessed
We included the following covariates for patients with diabetes;
glycated hemoglobin (HbA1c), systolic- and diastolic blood pressure,
low- and high-density lipoprotein cholesterol, triglycerides, total
cholesterol, body mass index, use of medications, smoking status,
duration of diabetes, estimated glomerular filtration rate and physical
activity level (categories: never, less than once a week, twice a week,
35 times per week, or daily). For each patient with diabetes, we
used imputed baseline values for risk factors, i.e., imputed values at
start of follow-up on January 1, 2020. Estimated glomerular filtration
rate was assessed according to the Modification of Diet in Renal Dis-
ease Equation. Macroalbuminuria was defined as a urinary albumin-
to-creatinine ratio >30 mg/mmol or a urinary albumin clearance of
>200 mg/min or >300 mg/L. For socioeconomic variables, we catego-
rized education into 9 years (pre-secondary education), > 9 to12 years (secondary education) and  12 years (post-secondary edu-
cation). Income was stratified into annual quintiles. Marital status
was dichotomized into married and not-married, while country of
birth was labeled as Scandinavian and other ethnicities.
Information on diabetes specific risk factors were not assessed in
main analyses, they were included in regression models for ancillary
analyses, i.e. optimal levels of risk factors and relative importance of
risk factors. For the analyses of optimal risk factor levels, the follow-
ing risk factors and cut-offs were considered: glycated haemoglobin
(6.9% [53 mmol/mol]), systolic and diastolic blood pressure (either
130 mmHg systolic or 80 diastolic), estimated glomerular filtra-
tion rate (< 90 mL/min/1,73 m2), low-density lipoprotein cholesterol
(>2.5 mmol/L) and body mass index (< 25 kg/m2).
2.4. Statistical analysis
For each outcome, we analysed age- and sex standardized inci-
dence rates, the rates were standardized to the age and sex distribu-
tion in the general population of Sweden, 2019. In the incidence
analyses, each person with diabetes was matched with approxi-
mately five region-, age- and gender controls, randomly selected
from the general population. Numerators were the number of first
events in a particular time period (i.e. month), and denominators
were the number of persons at risk during the same time period.
Standardized incidence rates are presented as events per 1,000
patient-years of observation with 95% confidence intervals. In addi-
tion, crude incidence rates were calculated for all outcomes and pre-
sented as events per 1,000 patient-years of observation with 95%
confidence intervals. Follow-up was stratified according to eight one-
month periods for all outcomes. All study participants were followed
from the index date (January 1, 2020) until death or end of follow-up.
Patients and controls with non-fatal outcomes continued to contrib-
ute with person-years and events for remaining outcomes. If controls
died from non-COVID related causes after start of follow-up, they
were right censored.
We constructed Cox proportional hazard models for all outcomes
to compare excess risk between patients with diabetes and matched
controls. Cox regression models for primary analyses included age,
sex, socioeconomic factors, comorbidities at baseline, pharmacologi-
cal treatment and a “Category” variable denoting patient with diabe-
tes or control. In order to optimize model performance and
determine accurate relative risk, age was modelled as either a contin-
uous- or categorical variable, depending on the outcome and patient
cohort. Additionally, we performed stratified Cox regression models
on patients with type 1 diabetes, type 2 diabetes and their matched
controls, respectively. Ethnicity was initially included in the regres-
sion models, however, due to few events in the separate ethnic
groups, this covariate resulted in inflated hazard ratios and was
therefore excluded from the analyses. In addition to this, we con-
structed Cox models that were adjusted for age and sex, in order to
estimate excess risk for primary outcomes among patients with dia-
betes, compared to matched controls, using no further adjustment
for confounders.
Furthermore, we assessed the hazard risk functions for glycated
haemoglobin, systolic blood pressure, low-density lipoprotein cho-
lesterol, body mass index and estimated glomerular filtration rate, by
modelling the association between each risk factor and the outcomes
using restricted cubic splines with 4 knots for appropriate covariates.
The evidence-based target level was set as reference for each risk fac-
tor. Relative importance provides an estimate of how important each
risk factors is in terms of predicting the outcome. In Cox regression
models for patients with diabetes, we used imputed baseline values
for risk factors, i.e. measured values observed at start of the study.
We used the estimated explained relative risk measure (R2 value)
and proportion of explainable log-likelihood explained by each risk
factor (Wald X2), to assess the partial effect of each risk factor. These
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disposed to interpret continuous variables as more important than
categorical variables, whereas, the analysis of explainable log-likeli-
hood method results in more accurate assessment of categorical vari-
ables, since all covariates are categorized in this model.
Missing data were imputed with the Multivariate Imputation by
Chained Equations (MICE) algorithm. We imputed 2 complete data
sets; variables used in the imputation are similar to variables used in
the Cox models for patients with diabetes. Because of the exploratory
nature of this study, two-sided P values of less than 0.05 were consid-
ered to indicate statistical significance. No adjustments were made
for multiple comparisons, thus, the outcome of individual hypothesis
tests should be interpreted with caution. All analyses were performed
in RStudio (v 4.0.2).
2.5. Study design and support
The study was designed by the first and last author. All authors
participated in data collection, analysis and interpretation, vouch for
the accuracy and completeness of the data and analyses, and made
the decision to submit the manuscript for publication. The Swedish
Ethical Review Authority approved the study. Funding sources had
no role in study design, data collection, data analysis, interpretation
or writing of the report.
3. Results
3.1. Study population and outcomes
We identified 44,639 patients with type 1 diabetes and 204,919
matched controls, referred to as the type 1 case control cohort, and
411,976 persons with type 2 diabetes and 1,948,900 matched con-
trols from the general population, referred to as the type 2 case con-
trol cohort. Baseline characteristics for patients with diabetes and
their matched controls are presented in Table 1. Mean age among
patients with type 1 diabetes was 426 years and 437% were women,
whereas patients with type 2 diabetes were 661 years on average
and 443% were women. Baseline characteristics by each outcome for
patients and controls are presented in supplementary table S2S4.
During the study period there were 10,486 hospitalizations, 1,416
admissions into intensive care (where all but 60 cases overlapped
with hospitalizations), and 2,995 deaths. Death rates for hospitaliza-
tions and admissions into intensive care were 122% and 226%, corre-
sponding to 1,280 and 320 deaths respectively, while 1,395 of the
deaths (466%) took place among individuals that were not hospital-
ized (the latter mainly occurred in long-term care facilities as
reported by the Swedish National Board of Health and Welfare
(https://www.socialstyrelsen.se/en/about-us/).
3.2. Hospitalization
Incidence rates standardized for age and sex for hospitalizations
were higher in individuals with diabetes, compared to controls (Fig.
1 Panel A), peaking in April at 2201 and 3234 cases per 1000 per-
son-years in type 1 and type 2 diabetes, respectively, while the corre-
sponding figures for controls were 98 and 1203. Crude and
standardised rates for hospital admissions, admissions into intensive
care and deaths in type 1 and 2 diabetes are shown in supplementary
Tables S5-S7. Age- and sex-adjusted hazard ratios (HRs) for being
hospitalized in patients with type 2 diabetes, compared to controls,
was 222, 95% CI 213-232, (Supplementary figure S2). The corre-
sponding hazard for type 1 diabetes was 210, 95% CI 172-257.
In the type 2 case control cohort patients with type 2 diabetes dis-
played 40% higher risk (HR 140, 95% CI 134-147) for hospitalization
with COVID-19, compared to controls (Fig. 2), after adjustment for
education, income, treatment and comorbidities, while type 1diabetes was not independently associated with this outcome
(adjusted HR 125, 95% CI 097  162) (Fig. 3). The risk associated
with age in the type 2 case control cohort displayed a non-linear rela-
tionship where only younger age categories (i.e. 45-54 and 55-64)
were more likely to be hospitalized. Hypertension (HR 295, 95% CI
277  313), dementia (HR 223, 95% CI 206  242) and renal dis-
ease (HR 282, 95% CI 267  297) displayed the highest risk for hos-
pitalization in the type 2 case control cohort. Antihypertensive
medication (HR 0.70, 95% CI 0.66  0.74) and statins (HR 0.87, 95% CI
0.83  0.92), were associated with lower risk, whereas treatment
with antithrombotics or anticoagulants was associated with higher
risk.
In supplementary Table S8, adjusted Cox regression results of
hospitalization for COVID-19 are presented separately for patients
with type 1 and type 2 diabetes, and their matched controls. In type 1
diabetes, compared to individuals aged <45 years, those aged 45 to
54 years were twice as likely to require hospital care, while persons
65 and older were three times more likely to be hospitalized.
Women, compared to men, with type 1 diabetes did not have a signif-
icantly lower risk for hospitalization, HR 090 (95% CI 064-128)
while female sex did, HR 072 (95% CI 056-093). Heart failure (HR
204, 95% CI 120  346), hypertension (205, 95% CI 118  355),
asthma (HR 196, 95% CI 119  323), renal disease (HR 199, 95% CI
134  295), and using antithrombotics (HR 157, 95% CI 100  246)
or anticoagulants (HR 276, 95% CI 155  492) were all associated
with increased likelihood of hospitalization in diabetes type 1. In
patients with type 2 diabetes, all age groups above the age of 65 were
less likely to be hospitalized than those younger than 45, while,
among controls, most age categories older than 45 were more likely.
3.3. Admission to intensive care
In patients with diabetes, admissions to intensive care per 1,000
person-years increased during March and peaked during April for
type 2 diabetes at 661 and 363 for type 1 diabetes (Fig. 1 Panel B),
with corresponding rates for their respective controls 175 and 103
per 1,000 person-years. The age- and sex-adjusted hazard ratio for
being admitted to intensive care in patients with type 2 diabetes and
type 1 diabetes, compared to controls was 249, 95% CI 222-279 and
208, 95% CI 122-350, respectively (Supplementary figure S2).
In the type 2 case control cohort type 2 diabetes was associated
with increased likelihood to be admitted to intensive care (HR 136,
95% CI 119  155), compared to controls, after full adjustment
(Fig. 2 Panel B). Higher income and female sex were protective,
whereas being married, atrial fibrillation, hypertension, chronic
obstructive pulmonary disease, asthma and renal disease were asso-
ciated with increased likelihood. Treatment with antihypertensives
and antithrombotics and anticoagulants were associated with lower
risk.
In the type 1 case control cohort, female sex, history of coronary
heart disease, treatment with antihypertensives and statins were
associated with lower risk for intensive care, whereas hypertension,
renal disease and anticoagulants were associated with increased risk
(Fig. 3 Panel B). In patients with type 1 diabetes, the risk to be admit-
ted to intensive care was 500 (95% CI 110  2270) in patients with
heart failure, while renal disease was associated with the highest risk
(HR 121, 95% CI 471  3130) in controls (Supplementary Table S9).
Hypertension, asthma, and renal disease were associated with
increased risk among patients with type 2 diabetes and in their
matched controls.
3.4. Mortality
COVID-19 mortality rates were higher among patients with diabe-
tes throughout the entire follow-up period peaking during April with
death rates per 1000 person years of 785 and 755 in type 2 and 1
Table 1
Baseline characteristics of patients with diabetes and matched controls, along with descriptive data for primary events.
Type 1 diabetes controls Type 1 diabetes Type 2 diabetes controls Type 2 diabetes
Number of study participants (n) 204919 44639 1948900 411976
Sex = female (%) 91150 (44.5) 19514 (43.7) 890839 (45.7) 182652 (44.3)
Age (SD) 40.49 (15.42) 42.60 (16.56) 63.37 (12.21) 66.05 (13.24)
Age-categories (%)
<45 124448 (60.7) 24948 (55.9) 142465 (7.3) 26173 (6.4)
45-54 38792 (18.9) 8273 (18.5) 297226 (15.3) 54542 (13.2)
55-64 25269 (12.3) 5984 (13.4) 520342 (26.7) 91206 (22.1)
65-74 13812 (6.7) 4184 (9.4) 647852 (33.2) 125875 (30.6)
>75 2598 (1.3) 1250 (2.8) 341015 (17.5) 114180 (27.7)
Sociodemographic factors
Education (%)
Pre-secondary education  9 years 33508 (16.4) 7825 (17.5) 453334 (23.3) 139237 (33.8)
Secondary education >9 to 12 years 94605 (46.2) 21073 (47.2) 864551 (44.4) 185338 (45.0)
Post-secondary education  12 years 76806 (37.5) 15741 (35.3) 631015 (32.4) 87401 (21.2)
Marital status = Not married (%) 133885 (65.3) 28736 (64.4) 906198 (46.5) 206005 (50.0)
Ethnicity = Not Scandinavia (%) 18108 (8.8) 2849 (6.4) 235097 (12.1) 80931 (19.6)
Income family interquartile range (IQR) (%)
IQR 1 32486 (15.9) 8192 (18.4) 463023 (23.8) 141503 (34.3)
IQR 2 48550 (23.7) 11130 (24.9) 477297 (24.5) 115635 (28.1)
IQR 3 55477 (27.1) 11739 (26.3) 495158 (25.4) 90225 (21.9)
IQR4 68406 (33.4) 13578 (30.4) 513422 (26.3) 64613 (15.7)
Income interquartile range (IQR) (%)
IQR 1 79426 (38.9) 17674 (39.7) 412802 (21.3) 132480 (32.2)
IQR 2 47195 (23.1) 10938 (24.6) 478147 (24.6) 116281 (28.3)
IQR 3 43688 (21.4) 9092 (20.4) 510021 (26.3) 89811 (21.9)
IQR4 33730 (16.5) 6808 (15.3) 539640 (27.8) 72427 (17.6)
Primary outcomes
Covid hospitalization (%) 281 (0.1) 144 (0.3) 6618 (0.3) 3443 (0.8)
Admission to intensive care (%) 41 (0.0) 21 (0.0) 906 (0.0) 448 (0.1)
Covid death (%) 19 (0.0) 21 (0.0) 1801 (0.1) 1154 (0.3)
Comorbidities at baseline
Coronary heart disease (%) 4251 (2.1) 3490 (7.8) 178099 (9.1) 85814 (20.8)
Acute myocardial infarction (%) 2189 (1.1) 1736 (3.9) 85547 (4.4) 42581 (10.3)
Stroke (%) 2126 (1.0) 1357 (3.0) 85140 (4.4) 35793 (8.7)
Heart failure (%) 1941 (0.9) 1474 (3.3) 82138 (4.2) 44215 (10.7)
Valvular disease (%) 1193 (0.6) 528 (1.2) 43765 (2.2) 15278 (3.7)
Atrial fibrillation (%) 3667 (1.8) 1212 (2.7) 155352 (8.0) 56522 (13.7)
Hypertension (%) 14173 (6.9) 15474 (34.7) 498672 (25.6) 228441 (55.5)
Peripheral arterial disease (%) 571 (0.3) 1518 (3.4) 24512 (1.3) 15904 (3.9)
Chronic obstructive pulmonary disease (%) 1382 (0.7) 489 (1.1) 59848 (3.1) 21210 (5.1)
Dementia (%) 383 (0.2) 243 (0.5) 29509 (1.5) 10834 (2.6)
Asthma (%) 11178 (5.5) 2965 (6.6) 82731 (4.2) 26936 (6.5)
Alcoholism (%) 7950 (3.9) 2651 (5.9) 64353 (3.3) 16785 (4.1)
Substance abuse (%) 11317 (8.0) 3726 (8.4) 98096 (6.2) 29018 (7.5)
Schizophrenia (%) 2183 (1.5) 399 (0.9) 19910 (1.3) 8963 (2.3)
Renal disease (%) 1562 (0.8) 5470 (12.3) 45546 (2.3) 35382 (8.6)
Cancer (%) 10499 (5.1) 2701 (6.1) 339594 (17.4) 81715 (19.8)
Pharmalogical treatment
Antihypertensive medication (%) 30414 (14.8) 17262 (38.7) 849737 (43.6) 318206 (77.2)
Statins (%) 13296 (6.5) 18666 (41.8) 438688 (22.5) 270773 (65.7)
Anticoagulant medication (%) 5280 (2.6) 1620 (3.6) 189632 (9.7) 64292 (15.6)
Antithrombotic medication (%) 7229 (3.5) 6775 (15.2) 280676 (14.4) 126909 (30.8)
Variables from the National Diabetes Registry (NDR)
Age of onset of disease (SD) 17.65 (10.26) 56.90 (13.25)
Duration of diabetes (SD) 13.67 (11.87) 3.15 (5.34)
Glycated hemoglobin (HbA1c) (SD) 65.32 (17.31) 55.35 (17.65)
Glycated hemoglobin categories (%)
HbA1c < 48 mmol/mol 5503 (13.1) 144650 (39.1)
HbA1c >= 48 & HbA1c <= 53 mmol/mol 4899 (11.6) 81851 (22.1)
HbA1c >= 54 & HbA1c <= 58 mmol/mol 5314 (12.6) 40086 (10.8)
HbA1c >= 59 & HbA1c <= 74 mmol/mol 16015 (38.1) 58436 (15.8)
HbA1c >= 75 & HbA1c <= 85 mmol/mol 5647 (13.4) 17945 (4.8)
HbA1c >= 86 mmol/mol 4706 (11.2) 27452 (7.4)
Smoking = Yes (%) 5647 (14.3) 52696 (16.8)
Albuminuria (%)
Macroalbuminuria (>30) 1148 (4.0) 9106 (4.2)
Microalbuminuria (3-30) 2532 (8.9) 27431 (12.6)
No albuminuria 24662 (86.8) 180848 (82.8)
Normalized value 65 (0.2) 1013 (0.5)
Retinopathy (%) 4570 (28.5) 18794 (17.6)
Systolic blood pressure (SD) 123.27 (14.72) 136.54 (16.84)
(continued)
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Table 1 (Continued)
Type 1 diabetes controls Type 1 diabetes Type 2 diabetes controls Type 2 diabetes
Diastolic blood pressure (SD) 73.24 (8.91) 79.94 (9.96)
Total-cholesterol (SD) 4.61 (1.00) 5.10 (1.18)
High-density lipoprotein cholesterol (SD) 1.35 (0.31) 1.24 (0.30)
Triglycerides (mean (SD)) 1.15 (0.94) 2.05 (1.62)
Physical activity (%)
< 1/week 2253 (14.0) 31835 (13.5)
Daily 3668 (22.8) 72016 (30.6)
Never 1152 (7.2) 29645 (12.6)
Regularly 1-2/week 3673 (22.8) 48226 (20.5)
Regularly 3-5/week 5350 (33.2) 53616 (22.8)
Insulin treatment method = insulin pump (%) 4583 (19.4) 151 (0.4)
LDL-cholesterol (SD) 2.61 (0.83) 3.00 (1.01)
Estimated glomerular filtration rate (SD) 101.5 (29.52) 85.94 (24.76)
S-creatinine (SD) 73.00 (29.22) 74.99 (22.39)
Body mass index (SD) 24.78 (6.28) 30.84 (7.47)
SD denotes standard deviation.
Pharmacological treatment and comorbidities are presented as number of events that occurred or individuals with ongoing medical treatment and
(%).
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and 274 (Fig. 1). In age- and sex-adjusted analyses both type 1 and
type 2 patients, compared to controls, had an increased mortality risk
(HR 290, 95% CI 154-547 and 219, 95% CI 203-236, respectively)
(Supplementary figure S2). Of note, the number of deaths among
individuals with type 1 diabetes was very limited, only 21 cases, with
no death among patients aged <45 years.
In the type 2 case control cohort, diabetes was associated with
50% increased risk for death (HR 150, 95% CI 139  163) after full
adjustment (Fig. 2 Panel C). Risk rose steeply with age. Increasing
income and education were associated with lower risk (Fig. 2 Panel
C). In patients with type 2 diabetes antihypertensive treatment and
use of statins were associated with lower mortality risk. Virtually all
comorbidities were associated with increased mortality risk, with
dementia associated with the highest risk (HR 703, 95% CI 645 
765).
After full adjustment, type 1 diabetes did not display an increased
risk for death from COVID-19, compared to controls (HR 138, 95% CI
064-299) (Fig. 3 Panel C). In type 1 diabetes dementia and renal dis-
ease were associated with increased risk for succumbing to COVID-19
infection (Suppl Table S10). Most cardiovascular comorbidities,
chronic obstructive pulmonary disease, dementia and end stage renal
disease were associated with increased mortality risk in type 2 diabe-
tes and their controls. Statins and antihypertensives were associated
with reduced risk in diabetes type 2, with broadly similar reductions
in type 2 controls. In type 2 diabetes, increasing age displayed an
exponential risk association with mortality in the highest age-group
(ie 75 and older) HR 249, 95% CI 794 -782, compared to <45 years,
even more pronounced in matched controls (HR 421, 95% CI 174 
1020) (Suppl Table S10).
3.5. Risk factors for COVID-19 outcomes in type 1 and 2 diabetes
In Fig. 45, Panel AC, hazard risk functions are presented for
selected risk factors and hospitalization, admission to intensive care,
as well as mortality. Elevated glycated hemoglobin levels were asso-
ciated with increased risk for all outcomes, except for hospitalization
among patients with type 1 diabetes.
In type 2 diabetes, elevated systolic blood pressure and low-den-
sity lipoprotein cholesterol levels were associated with lower risk for
hospitalization and being admitted to intensive care, but not mortal-
ity (Fig. 4). In type 1 diabetes, elevated low-density lipoprotein cho-
lesterol was associated with increased risk for admission to intensive
care, while elevated body mass index was associated with a pro-
nounced increase in relative risk for all COVID-19 related outcomes
in both cohorts with diabetes. Increasing levels of glycatedhemoglobin in type 1 diabetes was associated with steeply increasing
mortality risk (Fig. 5 Panel C). In type 2 diabetes, estimated glomeru-
lar filtration rate displayed a polynomial risk function where low val-
ues were associated with lower risk for hospitalization and ICU-care.
For estimated glomerular filtration, marginally reduced levels below
therapeutic guideline values, was associated with lower risk for hos-
pitalization and admission to ICU in type 1 diabetes (Fig. 5 Panel A),
however, renal function was not associated with mortality in any of
the diabetes cohorts.
The relative importance plot for patients with diabetes is pre-
sented in Supplementary Figure S3 Panel AC, only covariates with
the greatest relative predictive contribution to the model are pre-
sented. For hospitalization and admission to intensive care, higher
age, renal disease, blood pressure and body mass index were the
strongest predictors in both cohorts with diabetes. For death from
COVID-19 in type 1 diabetes, duration of diabetes explained almost
40% of the relative predictability, considering all covariates included
in the model, with age adding another 20%. In type 2 diabetes, age,
dementia, ongoing lipid medication and renal disease were the stron-
gest predictors, derived from the R2 and chi-square models.
4. Discussion
During the first wave of the COVID-19 pandemic in Sweden dur-
ing the spring of 2020, these nationwide registry data show that indi-
viduals with type 2 diabetes had more than twice the likelihood for
COVID-19-related hospitalization, being admitted to intensive care
and death, compared to matched controls from the general popula-
tion. This excess risk was reduced but persisted after adjustment for
comorbidities and other factors. In age- and sex-adjusted analyses
patients with diabetes type 1 had significant excess risk for hospitali-
zation, intensive care, and death due to COVID-19, but after full
adjustment for confounders and mediators, individuals with type 1
diabetes did not display any independent excess risk for COVID-19
related outcomes. This is, to our knowledge, the first study to investi-
gate the relative and absolute risk of hospitalization, admission to
ICU and death from COVID-19 by type of diabetes in an entire nation,
and comparing them to a substantial proportion of the adult popula-
tion without diabetes.
Virtually all comorbidities were associated with significantly
higher risk for COVID-19 related outcomes among patients with
type 2 diabetes and matched controls. Being treated with antihy-
pertensive medications and statins were associated with lower
risk, whilst antithrombotics and anticoagulants were associated
with higher risk of outcomes. Similar patterns were observed for
type 1 diabetes and their matched controls. Those with higher
Fig. 1. Standardized incidence rates in patients with diabetes and matched controls for covid-19 related hospitalization, intensive-care and mortality
Legend: Controls were matched for age, sex, and county. I bars represent 95% confidence intervals. Incidence rates are presented as per 1000 person-years.
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in both patients with diabetes type 2 and the general population,
however, women, compared to men, with diabetes type 1 had no
significant reduction in risk.Most studies regarding prognosis in patients infected with COVID-
19 so far use case series or hospital-based populations; with short-
term mortality as an outcome [18]. A large nationwide study from
the UK based on over 60 million people observed that both type 1
Fig. 2. Hospitalization, mortality and intensive-care due to covid-19 in patients with type 2 diabetes and matched controls
Legend: Cox regression models for patients with type 2 diabetes and their matched controls.
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death with COVID-19 but did not investigate the risk of being hospi-
talized or requiring intensive care [6]. A recent study of the first wave
of the pandemic in Scotland found that the overall risks of fatal or
critical care unit-treated COVID-19 were substantially elevated in
those with type 1 and type 2 diabetes compared with the background
population. However, in the Scottish study 9 out of 10 cases were
fatal, at a mean age of 80 years [14]. In our study, the age distribution
of the three outcomes varied substantially, with fatal cases in type 2
diabetes on average 79 years, compared to 60 years for type 2 diabe-
tes admitted to intensive care. Corresponding figures for type 1 dia-
betes were 71 years for fatal cases and 54 years for intensive care.
There was very little overlap between intensive care and mortality,
with only 10.7% of deaths occurring in patients admitted to intensive
care.
In the present study type 1 diabetes was not independently asso-
ciated with excess risk for mortality indicating that the absolute risk
in diabetes type 1 was mediated through the long-term complica-
tions associated with this disorder. The contrasting findings to the
type 1 diabetes patients in the UK could reflect differences in dysgly-
cemia, obesity and smoking [19], among patients with type 1 diabe-
tes in the UK population, compared to the Swedish type 1 diabetes
population. Also, there were only 21 deaths, with ensuing lack of sta-
tistical power. Of note, although the age- and sex-adjusted hazard
ratios for outcomes in diabetes type 1 was at least 2-fold that of con-
trols, absolute risks were quite low. Persons with diabetes type 1were not specifically asked to shield, but there were still no deaths in
anyone with diabetes type 1 younger than 45 years.
Using hospitalization or intensive care as outcomes is not uncom-
plicated because of differences between nations in organization of
hospital care, and availability of beds. In the present study, higher
age among patients with type 1 diabetes was associated with
increased risk for hospitalization, admission to intensive care and
death. The increased likelihood of hospitalization with comorbidities
might be due not only to increasing risks of complications but also to
that these patients might be perceived to be at higher risk and admit-
ted on that account. In type 2 diabetes, with patients on average two
decades older, increasing age reduced the likelihood for admission
and intensive care, but not death from COVID-19, where older age
was associated with increased risk. Fewer admissions to intensive
care, given the higher mortality, in all likelihood represent selection
processes where elderly patients with multiple disorders, including
diabetes, will have been considered too frail to benefit from intensive
care or by being hospitalized. Of note, almost half of the deaths regis-
tered in the study occurred in persons who were not hospitalized,
the absolute majority of those deaths occurred in long-term care
facilities, with only 4% of deaths outside either hospital or residential
care.
Initially, reports were conflicting regarding the impact of diabetes
or dysglycemia, where some, but not all studies found a clear associa-
tion [13, 20, 21]. However, reports from China, Italy and England, are
unanimous that older patients with chronic diseases, including
Fig. 3. Hospitalization, mortality and intensive-care due to covid-19 in patients with type 1 diabetes and matched controls
Legend: Cox regression models for patients with type 1 diabetes and their matched controls. For statistical reasons, age was modeled as categories for hospitalization for COVID-
19, whereas age was modeled as a continuous variable in the regression models for admission to ICU and death, and all regression models does not include similar covariates.
A. Rawshani et al. / The Lancet Regional Health - Europe 4 (2021) 100105 9diabetes, are at higher risk for severe complications and death from
COVID-19 [6, 9, 22, 23]. Our regression models were extensively
adjusted for confounding factors, nevertheless, whether diabetes
itself increases susceptibility and impacts outcomes from COVID-19
infection, or whether it is the cardio-renal comorbidities frequently
associated with diabetes remains controversial. Additionally, we
found that ongoing treatment with antihypertensive medication and
statins were associated with lower risk for most outcomes, whereas
medication with anticoagulants and antithrombotics was associated
with increased risk. The observed association of increasing low-den-
sity lipoprotein cholesterol levels and lower risk for COVID-19 out-
comes may suggest that treatment with statins interferes positively
with prognosis of severe SARS-CoV2 infection, since individuals with
hyperlipidemia are more likely treated with statins. Theoretically,
medications more prevalent in the diabetes population, such as ACE-
inhibitors, may interfere with susceptibility and prognosis of SARS-
CoV-2 [24, 25].
Increasing levels of glycated hemoglobin in patients with type 2
diabetes was associated with higher risk for outcomes, in contrast to
patients with type 1 diabetes, where hyperglycemia was associated
with increased risk for admission to intensive care and death. Ele-
vated body mass index was associated with higher risk for all out-
comes in both cohorts with diabetes. Relative variable importance
assessment shows that age, renal disease, hypertension, chronic
obstructive pulmonary disease, asthma, high body mass index,
dementia and low-density lipoprotein cholesterol were the mostimportant predictors for COVID-19 outcomes. The lower risk for hos-
pitalization and admission to intensive care in patients with type 2
diabetes and increasing levels of low-density lipoprotein cholesterol
is likely due to reverse causation.
Reports suggest that patients with diabetes and SARS-CoV-2 may
develop pneumonia more frequently, which in turn is detrimental to
the prognosis of COVID-19. Immune studies show that poorly con-
trolled diabetes could inhibit lymphocyte response, and impairs the
monocyte-, macrophage- and neutrophil function [26, 27]. Also, stud-
ies show that COVID-19 is associated with coagulopathic and pro-
thrombotic conditions in particularly pulmonary microvasculature
but also in extrapulmonary organs. A Cochrane review combined
data from seven reports that included 5929 participants to investi-
gate the effect of anticoagulants, with conflicting results [28, 29].
Some limitations of our study should be considered. Polymerase
chain reaction (PCR) testing for the virus during the early phase of
the pandemic was not always performed, particularly not in deaths
occurring out-of-hospital, and diagnosis therefore rested on clinical
assessment. However, any misclassification due to the lack of testing
likely affected persons with and without diabetes to a similar degree.
Classification of diabetes was not based on islet autoantibodies or
measurement of C-peptide levels. We used the epidemiological defi-
nitions and these has been validated as accurate in 97% of the cases.
Correction for multiple testing was not performed, and thus caution
is needed with respect to the interpretation of significance tests. Hos-
pitalizations and need of intensive care, although a significant part of
Fig. 4. Hazard function for specific risk factors and covid19 related outcomes in patients with type 2 diabetes
Legend: Hazard risk function from cox regression for all outcomes using cubic splines for certain covariates. Model adjusted for age, glycated hemoglobin, body mass index,
blood pressure, cholesterol, triglycerides, HDL-C, LDL-C, eGFR, cumulative-LDL, diabetes-duration, smoking, albuminuria, physical activity, sex, coronary heart disease, stroke, heart
failure, valvular disease, atrial fibrillation, hypertension, peripheral arterial disease, chronic obstructive pulmonary disease, asthma, dementia, alcoholism, renal disease, cancer,
marital status, education, income, hypertensive medication, statins, anti-coagulants and antithrombotics.
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outcomes and are subject to availability of beds and resources, and to
the perception of risk in a patient, and may be rationed during an epi-
demic. Additionally, prognosis in COVID-19 is contingent on being
infected, which in turn is influenced by many factors, such as volun-
tary sheltering, housing, occupation, etc. where there is, so far,
incomplete information, not least because the capacity for testing for
the virus in the general population was limited during the first phase.
In conclusion, we report that type 2 diabetes was associated with
at least twice the risk for separate outcomes of hospitalization,
admission to intensive care and death due to COVID-19, compared to
the Swedish general population, and that after adjustment for comor-
bidities and mediators there was still a significant, albeit reduced
excess risk. Patients with type 1 diabetes did not display an excess
risk for outcomes after adjustment; reassuringly for this group, there
were very few deaths and admissions into intensive care, during the
first and second wave of the COVID-19 pandemic.
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